Sabra Health Care REIT, Inc. (SBRA)
—Data provided by IEX. Delayed 15 minutes.
$4.6B
$7.0B
26.3
6.22%
+8.6%
+7.3%
+821.1%
Explore Other Stocks In...
Valuation Measures
Financial Highlights
Balance Sheet Strength
Similar Companies
Company Profile
At a glance
• Managed Senior Housing as the New Growth Engine: Sabra's strategic pivot from triple-net leases to managed senior housing (SHOP) has created a bifurcated portfolio where 26% of NOI now grows at mid-teens rates while the traditional skilled nursing segment provides stable, bond-like cash flows. This transformation fundamentally alters the company's risk/reward profile, offering equity-like upside within a REIT structure.
• Capital Allocation Discipline as Competitive Moat: Management's ruthless portfolio pruning—exemplified by the Holiday transition and $550 million in 2025 acquisitions—demonstrates a quality-over-quantity approach that has achieved investment-grade ratings while peers struggle with overleveraged balance sheets. Healthcare REITs have historically been destroyed by bad deals, not bad operations.
• Portfolio Inflection Point: For the first time, skilled nursing exposure has dropped below 50% of the portfolio while SHOP targets 40% NOI contribution. This reduces Sabra's vulnerability to Medicaid reimbursement pressure while positioning the company to capture demographic tailwinds in senior housing.
• Execution Risk Concentration: The Holiday portfolio transition involving 21 facilities and three new operators represents a critical near-term catalyst. While performance bottomed in July 2025 and improved through Q3, the success of this $200 million relationship reset will determine whether Sabra can deliver on its elevated SHOP growth targets.
• Valuation at Inflection: Trading at 14.1x operating cash flow with a 6.2% dividend yield, Sabra trades at a discount to smaller peers like NHI (16.5x) despite superior scale and balance sheet quality. The investment-grade rating and $1.1 billion liquidity provide strategic optionality that is not reflected in the current multiple.
Price Chart
Loading chart...
Growth Outlook
Profitability
Competitive Moat
Financial Health
Valuation
Returns to Shareholders
Financial Charts
Financial Performance
Profitability Margins
Earnings Performance
Cash Flow Generation
Return Metrics
Balance Sheet Health
Shareholder Returns
Valuation Metrics
Financial data will be displayed here
Valuation Ratios
Profitability Ratios
Liquidity Ratios
Leverage Ratios
Cash Flow Ratios
Capital Allocation
Advanced Valuation
Efficiency Ratios
Sabra Health Care REIT: The SHOP Transformation Rewriting Healthcare Real Estate (NASDAQ:SBRA)
Executive Summary / Key Takeaways
-
Managed Senior Housing as the New Growth Engine: Sabra's strategic pivot from triple-net leases to managed senior housing (SHOP) has created a bifurcated portfolio where 26% of NOI now grows at mid-teens rates while the traditional skilled nursing segment provides stable, bond-like cash flows. This transformation fundamentally alters the company's risk/reward profile, offering equity-like upside within a REIT structure.
-
Capital Allocation Discipline as Competitive Moat: Management's ruthless portfolio pruning—exemplified by the Holiday transition and $550 million in 2025 acquisitions—demonstrates a quality-over-quantity approach that has achieved investment-grade ratings while peers struggle with overleveraged balance sheets. Healthcare REITs have historically been destroyed by bad deals, not bad operations.
-
Portfolio Inflection Point: For the first time, skilled nursing exposure has dropped below 50% of the portfolio while SHOP targets 40% NOI contribution. This reduces Sabra's vulnerability to Medicaid reimbursement pressure while positioning the company to capture demographic tailwinds in senior housing.
-
Execution Risk Concentration: The Holiday portfolio transition involving 21 facilities and three new operators represents a critical near-term catalyst. While performance bottomed in July 2025 and improved through Q3, the success of this $200 million relationship reset will determine whether Sabra can deliver on its elevated SHOP growth targets.
-
Valuation at Inflection: Trading at 14.1x operating cash flow with a 6.2% dividend yield, Sabra trades at a discount to smaller peers like NHI (16.5x) despite superior scale and balance sheet quality. The investment-grade rating and $1.1 billion liquidity provide strategic optionality that is not reflected in the current multiple.
Setting the Scene: The Healthcare REIT at a Crossroads
Sabra Health Care REIT, incorporated in May 2010 as a spin-off from Sun Healthcare Group, began life as a traditional triple-net REIT focused on skilled nursing facilities. For a decade, the company followed the standard healthcare REIT playbook: acquire properties, lease them to operators, collect predictable rent escalations, and distribute the cash to shareholders. This model worked until it didn't. The pandemic exposed the fragility of operator-dependent cash flows and the concentration risk inherent in a skilled nursing-heavy portfolio.
Today, Sabra operates 363 properties across the U.S. and Canada, but the composition tells a different story. The portfolio includes 217 skilled nursing/transitional care facilities, 32 senior housing leased properties, 83 senior housing managed communities (SHOP), 16 behavioral health facilities, and 15 specialty hospitals. More importantly, the SHOP segment has grown from 20% to 26% of annualized cash NOI in just three quarters, with management targeting 40%. This shift places Sabra at the intersection of two powerful trends: the aging demographic wave creating unprecedented demand for senior housing, and the post-pandemic realization that operational control generates superior returns than passive ownership.
The healthcare REIT industry structure underscores the importance of this evolution. The sector is dominated by giants like Welltower (WELL) ($140 billion market cap) and Ventas (VTR) ($38 billion), which command premium valuations through scale and diversification. Sabra's $4.8 billion market cap makes it a mid-tier player, but one with a focused strategy that larger competitors cannot easily replicate. While Welltower and Ventas pursue massive portfolio acquisitions, Sabra has become a specialist in operator relationships and capital recycling—a strategy that requires patience and discipline that scale often precludes.
History with Purpose: From Passive Owner to Active Operator
Sabra's transformation didn't happen by accident. The 2017 merger with Care Capital Properties doubled the skilled nursing portfolio but also introduced management to the limits of triple-net leasing. Post-pandemic, the company embarked on a deliberate "cleanup and repositioning" that saw the portfolio shrink from 416 properties in early 2022 to 363 today. This wasn't shrinkage for shrinkage's sake; it was surgical removal of underperforming assets to fund higher-quality investments.
The February 2023 establishment of a $500 million ATM program signaled management's confidence in its ability to deploy capital accretively. By 2024, this confidence manifested in the Holiday portfolio decision. The Holiday relationship, dating to 2015, had underperformed post-pandemic despite effective crisis management. Rather than accept mediocrity, Sabra initiated a complex transition to three new operators—Discovery, In Spirits, and Sunshine Retirement Living—targeted for early 2025. This demonstrates a willingness to disrupt stable cash flows for the promise of superior growth, a trade-off many REIT managers avoid.
The acceleration in 2025, with over $550 million in closed and awarded deals, shows this strategy hitting its stride. These investments are 90-95% weighted toward SHOP, with a bias toward assisted living and memory care over independent living. They are domestic, newer vintage assets (5-7 years old), often with care components, and located primarily in the eastern U.S. This specificity reveals that Sabra isn't chasing any deal—it is building a curated portfolio of assets where operational expertise can drive mid-teens NOI growth.
Capital Allocation: The Discipline Behind the Transformation
Sabra's capital allocation philosophy is perhaps its most underappreciated competitive advantage. Management has repeatedly stated they are "not interested in building a loan book" or pursuing "complex JV kind of structures or mezz debt." Instead, they prefer "straightforward kind of simple to understand traditional deals." The healthcare real estate market is currently flooded with private equity capital chasing yield through complicated structures. Sabra's refusal to compete on complexity allows it to avoid the hidden risks that have plagued peers.
The July 2025 refinancing of $500 million in 2026 senior unsecured notes with a new term loan at SOFR + 120 bps (effectively fixed at 4.64%) exemplifies this discipline. The transaction extended weighted average debt maturity from 4 years to nearly 5 years while reducing the weighted average interest rate by 10 basis points to 4.04%. CFO Michael Costa noted the effective rate is "meaningfully lower" than what would have been achieved in the unsecured bond market. Sabra can access capital more cheaply than competitors, a direct benefit of its September 2025 investment-grade rating upgrade from Moody's.
The new $750 million ATM program established in August 2025, replacing the original $500 million program, provides leverage-neutral funding for the SHOP expansion. With $157.3 million in forward sale agreements outstanding at an average price of $18.14 per share, management has pre-funded investments at attractive levels. This eliminates the need for dilutive equity raises at inopportune times, a common pitfall for growing REITs.
Financial Performance: Two Portfolios, Two Stories
Sabra's financial results reveal a company operating two distinct business models simultaneously. The triple-net portfolio generated $90 million in cash rental income in Q1 2025, up slightly from $89 million despite $115 million in 2024 dispositions. Skilled nursing EBITDARM coverage hit an all-time high of 2.19x in Q1, while senior housing triple-net coverage reached 1.41x. These metrics show the legacy portfolio is not deteriorating—it is providing stable, bond-like cash flows that fund the dividend and de-risk the balance sheet.
The SHOP portfolio tells a radically different story. Same-store cash NOI grew 13.3% year-over-year in Q3 2025, or 15.9% excluding the 16 former Holiday properties. Occupancy increased 110 basis points to 86%, with the domestic portfolio up 90 basis points to 82.6% and the Canadian portfolio up 150 basis points to 93.1%. RevPAR grew 3.4% while exPOR remained flat, indicating operators are gaining pricing power as occupancy rises. This demonstrates the operational leverage inherent in the SHOP model—revenue growth flows directly to NOI when expense growth is controlled.
The total managed portfolio (including non-stabilized communities) saw cash NOI up 18.6% sequentially in Q3, with margins expanding 90 basis points. This acceleration shows the portfolio is hitting an inflection point where scale and operational improvements compound. Management's guidance for mid-teens same-store SHOP NOI growth for the full year appears increasingly conservative given the Q3 trajectory.
The Holiday Transition: A Real-Time Case Study
The Holiday portfolio transition represents Sabra's transformation in microcosm. The 21 facilities, moved to SHOP in early 2025, bottomed in July but showed improvement in August and September. CEO Rick Matros explained that the new operators' first priority was "rightsizing and stabilizing labor" because "even in IL, there's been some acuity creep and the lack of appropriate staffing... contributed to greater move-outs." This reveals the operational complexity that triple-net leases obscure. Sabra is now directly addressing the root causes of underperformance rather than simply collecting rent from struggling operators.
The transition allowed Sabra to expand relationships with Discovery, In Spirits, and Sunshine Retirement Living—operators specifically chosen for their operational expertise. This diversifies operator concentration while partnering with proven managers who can execute the SHOP model. The performance improvement in Q3, while early, suggests the strategy is working. If these facilities can achieve the 86% occupancy and mid-teens NOI growth of the broader SHOP portfolio, the $200 million investment will generate substantial value creation.
Competitive Positioning: The Specialist Advantage
Sabra's competitive position is best understood through contrast with its larger peers. Welltower, with $140 billion market cap and 112,641 senior housing units, operates at a scale that Sabra cannot match. However, Welltower's size makes it difficult to pursue the granular operator relationships and asset-level optimizations that drive Sabra's SHOP outperformance. While Welltower grows senior housing NOI at 10-12%, Sabra's SHOP portfolio delivers 13-16% growth. Specialization can trump scale in specific niches.
Ventas, with its RIDEA platform, competes directly in managed senior housing but carries the baggage of medical office exposure (~10% vacancy) and life sciences diversification that Sabra avoids. Ventas' 15.9% senior housing NOI growth is comparable to Sabra's, but achieved through a more complex organizational structure. Sabra's simpler, more focused approach may offer better transparency and lower overhead.
Omega Healthcare (OHI) presents the clearest contrast. With 80% of its portfolio in skilled nursing, OHI is essentially a pure-play bet on SNF reimbursement stability. While OHI's operating margins appear higher at 66% due to its lease-heavy model, this masks the underlying operational risk. Sabra's diversification into SHOP reduces Medicaid exposure while capturing senior housing tailwinds. OHI's 8-10% NOI growth pales beside Sabra's SHOP performance.
National Health Investors (NHI), at $3.8 billion market cap, operates at a similar scale but pursues a loan-heavy strategy (~40% of investments). While this provides liquidity, it limits operational upside. Sabra's property-focused approach, combined with its SHOP conversion capability, offers a more direct path to value creation from demographic trends.
Risks: Where the Thesis Can Break
The most immediate risk is execution of the Holiday transition. While Q3 showed improvement, 21 facilities represent significant operational complexity. If the new operators cannot stabilize occupancy and expenses, the drag on SHOP performance could persist into 2026, undermining the growth narrative. Management has set aggressive targets based on the assumption that transitioned assets will perform like the legacy SHOP portfolio.
SHOP operational risk itself is a structural concern. The triple-net model's appeal lies in its simplicity—operators bear all operational risk. By moving to SHOP, Sabra assumes responsibility for expense control, staffing, and occupancy. While current results are strong, any deterioration in labor markets or expense inflation could compress margins quickly. The 4% wage inflation trend, while stable, remains the largest expense component and a potential vulnerability.
Medicaid reimbursement pressure represents the existential risk for any SNF-heavy REIT. While management highlights "natural guardrails"—bipartisan congressional support, governor reliance on Medicaid matching funds, and strong portfolio coverage—the $880 billion in unspecified cuts proposed in House budgets creates uncertainty. Sabra's sub-50% SNF exposure mitigates this risk relative to OHI, but a severe reimbursement cut would still impact 37% of revenues derived directly or indirectly from skilled nursing.
Competition for quality assets is intensifying. Private equity buyers are returning to the market, and strategic buyers like large operator platforms can pay more because they value assets based on "revenue generated for all their acquired businesses." This could limit Sabra's ability to find accretive deals, forcing the company to accept lower initial yields or miss its growth targets.
Valuation Context: The Price of Transformation
At $19.28 per share, Sabra trades at 14.1x operating cash flow and 6.45x sales, with a 6.22% dividend yield. The enterprise value of $7.20 billion represents 15.81x EBITDA. These multiples place Sabra at a discount to smaller, less diversified peers. National Health Investors trades at 16.5x operating cash flow despite lower growth and no SHOP exposure. Omega Healthcare trades at 15.84x operating cash flow with pure-play SNF risk.
The balance sheet strength justifies a premium. Net debt to adjusted EBITDA of 4.96x is below the 5x long-term target, and the investment-grade rating from all three agencies provides access to capital at rates unavailable to sub-investment-grade REITs. The $1.1 billion liquidity position—comprising $200 million cash, $718 million revolver availability, and $157 million forward equity—provides strategic optionality that is not reflected in the current multiple.
The dividend payout ratio of 164% appears alarming, but this reflects the temporary drag of transition costs and non-cash items. Cash NOI growth of 13-16% in the SHOP portfolio and stable triple-net coverage above 2x suggests the dividend is covered by recurring cash flows. The forward equity program, with shares sold at an average $18.14 price, provides leverage-neutral funding for growth investments that should drive AFFO per share accretion in 2026.
Conclusion: The Compounding Effect of Discipline
Sabra Health Care REIT stands at an inflection point where strategic discipline meets demographic opportunity. The company's transformation from passive triple-net owner to active SHOP operator is not merely a portfolio shift—it is a fundamental reimagining of how healthcare real estate creates value. The 26% SHOP NOI contribution, growing at mid-teens rates, provides an earnings engine that traditional healthcare REITs cannot match, while the sub-50% skilled nursing exposure reduces policy risk.
The central thesis hinges on two variables: the successful integration of the Holiday portfolio and the continued availability of accretive SHOP investments. Early indicators on both fronts are positive, with transitioned facilities showing sequential improvement and a robust pipeline of newer vintage assets. The investment-grade balance sheet and $1.1 billion liquidity provide the firepower to execute this strategy without diluting shareholders at unfavorable prices.
For investors, Sabra offers a rare combination: a 6.2% dividend yield supported by stable triple-net cash flows, plus equity-like growth from the SHOP transformation. The valuation discount to peers reflects market skepticism about execution risk, but this skepticism creates opportunity. If management delivers on its 40% SHOP target while maintaining capital discipline, the current 14x cash flow multiple will likely expand as the market rewards the higher-growth, higher-quality earnings stream. The story is not without risk, but the margin of safety provided by the legacy portfolio and the upside optionality from the SHOP transformation create an asymmetric risk/reward profile that is increasingly difficult to find in today's REIT market.
If you're interested in this stock, you can get curated updates by email. We filter for the most important fundamentals-focused developments and send only the key news to your inbox.
Disclaimer: This report is for informational purposes only and does not constitute financial advice, investment advice, or any other type of advice. The information provided should not be relied upon for making investment decisions. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.
Loading latest news...
No recent news catalysts found for SBRA.
Market activity may be driven by other factors.
Discussion (0)
Sign in or sign up to join the discussion.